ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 147,87
0,22%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Omeros Corporation (OMER)

  7. Omeros Corporation (OMER) Actualités

OMER

Omeros (OMER)

Omeros Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:OMER
DateHeureSourceTitreSymboleSociété
12/06/202422h48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
07/06/202423h13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
04/06/202415h00Business WireOmeros Announces Webcast Details for Annual Meeting of ShareholdersNASDAQ:OMEROmeros Corporation
03/06/202415h00Business WireOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028NASDAQ:OMEROmeros Corporation
15/05/202422h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
15/05/202422h02Business WireOmeros Corporation Reports First Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
10/05/202414h50Business WireOmeros Corporation to Announce First Quarter Financial Results on May 15, 2024NASDAQ:OMEROmeros Corporation
09/05/202414h50Business WireOmeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid CongressNASDAQ:OMEROmeros Corporation
01/04/202422h02Business WireOmeros Corporation Reports Fourth Quarter and Year-End 2023 Financial ResultsNASDAQ:OMEROmeros Corporation
27/03/202413h30Business WireOmeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024NASDAQ:OMEROmeros Corporation
20/02/202415h00Business WireOmeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathyNASDAQ:OMEROmeros Corporation
14/02/202412h05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:OMEROmeros Corporation
01/02/202415h11Business WireOmeros Corporation Announces Additional Royalty Monetization with DRI Healthcare TrustNASDAQ:OMEROmeros Corporation
29/01/202421h26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:OMEROmeros Corporation
09/11/202322h02Business WireOmeros Corporation Reports Third Quarter 2023 Financial ResultsNASDAQ:OMEROmeros Corporation
06/11/202314h00Business WireOmeros Corporation to Announce Third Quarter Financial Results on November 9, 2023NASDAQ:OMEROmeros Corporation
03/11/202314h05Business WireOmeros Announces Online Publication in Advance of ASH Annual Meeting Detailing Narsoplimab Treatment Under Compassionate Use of 15 Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic MicroangiopathyNASDAQ:OMEROmeros Corporation
02/11/202314h05Business WireOmeros Corporation Announces Upcoming Presentations at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
19/10/202314h30Business WireOmeros Corporation Hires Andreas Grauer M.D. as Chief Medical OfficerNASDAQ:OMEROmeros Corporation
16/10/202313h30Business WireOmeros Corporation Provides Update on Interim Analysis of ARTEMIS-IGAN Phase 3 Trial of Narsoplimab in IgA NephropathyNASDAQ:OMEROmeros Corporation
20/09/202322h47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:OMEROmeros Corporation
09/08/202323h20Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:OMEROmeros Corporation
09/08/202314h00Business WireOmeros Corporation Reports Second Quarter 2023 Financial ResultsNASDAQ:OMEROmeros Corporation
04/08/202314h00Business WireOmeros Corporation to Announce Second Quarter Financial Results on Morning of August 9, 2023NASDAQ:OMEROmeros Corporation
28/06/202301h31Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:OMEROmeros Corporation
12/06/202314h45Business WireOmeros Corporation Announces Availability on Its Website of Materials Accompanying Presentations of OMS906 Data at the 2023 European Hematology Association CongressNASDAQ:OMEROmeros Corporation
01/06/202317h00Business WireOmeros Corporation Announces Late-Breaking Presentation of OMS906 Data at the 2023 European Hematology Association (EHA) CongressNASDAQ:OMEROmeros Corporation
22/05/202323h42Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:OMEROmeros Corporation
17/05/202323h07Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:OMEROmeros Corporation
17/05/202322h08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:OMEROmeros Corporation
 Showing the most relevant articles for your search:NASDAQ:OMER

Dernières Valeurs Consultées

BIT
UC2742
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés